

Est.
1841

YORK
ST JOHN
UNIVERSITY

Hobson, H and Petty, Stephanie ORCID
logoORCID: <https://orcid.org/0000-0002-1453-3313> (2021) Moving
forwards not backwards: heterogeneity in autism spectrum
disorders. *Molecular Psychiatry*.

Downloaded from: <https://ray.yorks.ac.uk/id/eprint/5524/>

The version presented here may differ from the published version or version of record. If
you intend to cite from the work you are advised to consult the publisher's version:
<https://www.nature.com/articles/s41380-021-01226-7>

Research at York St John (RaY) is an institutional repository. It supports the principles of
open access by making the research outputs of the University available in digital form.
Copyright of the items stored in RaY reside with the authors and/or other copyright
owners. Users may access full text items free of charge, and may download a copy for
private study or non-commercial research. For further reuse terms, see licence terms
governing individual outputs. [Institutional Repository Policy Statement](#)

RaY

Research at the University of York St John

For more information please contact RaY at ray@yorks.ac.uk

Moving forwards not backwards: heterogeneity in autism spectrum disorders

Hobson, H.^{1*}, & Petty, S.^{1,2}

¹Department of Psychology, University of York, UK

²North Yorkshire NHS Adult Autism and ADHD Assessment service, The Retreat York

*Corresponding author. Email contact: Hannah Hobson, hannah.hobson@york.ac.uk

The article by Mottron and Bzdok¹ argues that heterogeneity in autism is artefactual, and that returning to a “prototypical” autism would benefit clinical practice and research endeavours. We note that the authors do not define what they mean by “prototypical” autism and thus it is left for the reader to interpret who would and would not be included under the authors’ revised definition. However, from our reading, we argue that, though perhaps unintended, the suggestion is for a return to a rather stereotyped understanding of autism, one which is no longer fit for purpose and that research does not support: we offer our insights from both clinical and academic practice.

A move away from the (assumed) prototypical approach to autism proposed by Mottron and Bzdok¹ has, in fact, only recently taken place. One familiar autistic presentation – that of young males of mid-intellect without neurodevelopmental or mental health comorbidities - has been consistently favoured and has repeated from the original clinical observations of autism² to contemporary research sampling; for example, individuals with comorbid intellectual disability, who have mental health comorbidities, or who are female are consistently left out of research samples^{3,4}. This approach maintains a narrow lens of what autism looks like. It may offer a simpler scientific case, but it is biased, only examining a subsection of the autistic population, and is ultimately invalid. Indeed, the authors’ suggestions, if ever implemented, would likely lead to even poorer rates of identification for women and adults who did not have the opportunity to be diagnosed in childhood. A definition that incorporates data from females^{5,6}, adults, people with mental health comorbidities and comorbidity with conditions such as ADHD would contribute to an updated description, and not a less accurate description. Importantly, these updated definitions⁷ provide the basis for better clinical care through the design and refinement of updated interventions, such as for anxiety and depression⁸.

28 Indeed, the current evidence does not support the notion that narrowing our focus will resolve
29 the question of the biological underpinnings of autism. Three previous subtypes of autism under the
30 DSM-IV, PDD-NOS, autistic disorder and Asperger's Syndrome, have more in common in their
31 genetic underpinnings than differences⁹. This does not support the authors' view that one previous
32 subtype is muddying the waters. This also comes in the context of a broader genetic picture, in which
33 evidence suggests shared genetic factors between neurodevelopmental conditions, as well as within
34 them¹⁰. Furthermore, Happe and colleagues¹¹ have demonstrated that the social, communication and
35 repetitive interest symptoms of autism (now considered a dyad of social and non-social impairments⁷)
36 have independent genetic bases, and as such individuals are going to vary along three different
37 continua, leading inevitably to a very heterogeneous population.

38 Mottron and Bzdok¹ complain of shrinking effect sizes in the field. However, we note that as
39 factors such as sample sizes in research studies increase, the uncertainty around effect size estimates
40 will reduce: while this may appear to suggest a reduction in the effect sizes themselves, it may in fact
41 reflect improving precision and reproducibility¹², qualities we feel supersede effect sizes in
42 importance.

43 Where we can agree with the authors is that we (as clinicians and researchers) want valid,
44 specific and reliable diagnosis with high predictive accuracy, and a clear diagnostic threshold, which
45 considers functional impairment, and enables discounting differential diagnoses. Such diagnostic
46 practices are in the best interest of individuals, their families and health services offering support. The
47 authors appear to assume this does not happen in the clinic, but in our experience, differential
48 diagnosis and careful clinical judgment leads. And we are not alone: Molloy et al¹³ report the
49 diagnostic practices in their clinic and emphasise that quantitative scores generated from standardised
50 assessment tools such as the ADOS may be helpful, but the activities and interactions that such tools
51 scaffold support clinicians to build qualitative impressions: it is these impressions that make key
52 contributions to a diagnostic decision. Unlike the portrayal in Mottron and Bzdok¹, it is simply
53 inaccurate to suggest that people who score above threshold on the ADOS are automatically granted a
54 diagnosis.

55 Nonetheless, used as a laboratory test, misclassifications via the ADOS may occur. Here, we
56 argue that assessments used for research purposes only do need to be treated with caution: autism
57 researchers who have limited or no clinical experience may well not have the expertise to make
58 differential diagnoses, and misclassification may have ramifications for the autism samples included
59 in research studies. Perhaps the weight of the dilemma rests within research sampling rather than
60 clinical practice. One suggestion would be for researchers to ensure that their autistic samples have a
61 diagnosis given by an appropriate clinic (for example as done by Underwood and colleagues¹⁴). Of
62 course, such studies may replicate the biases and barriers faced by certain groups in achieving an
63 autism diagnosis: an alternative would be to look to population-based studies with more representative
64 real-world sampling (e.g. meta-analyses of clinic and population-based studies suggest many women
65 who meet the clinical threshold for autism do not proceed to clinical services for diagnosis¹⁵). The
66 tensions of ensuring classification accuracy and representation in research will need ongoing
67 discussion in our field. We also recommend that researchers give fuller descriptions of their samples,
68 such as functional ability, mental health cooccurrence, and medication status – to name just a few
69 important variables along which there is much heterogeneity in the autistic population - to help inform
70 future clinical care and scientific understanding.

71 We sympathise with the frustrations that come with the heterogeneity of autism, and a desire
72 to reduce the complexity surrounding its presentation and aetiologies. But we argue that we should
73 not sacrifice validity for the sake of simplicity, particularly at the personal cost of many people who
74 already face significant barriers to being diagnosed, nor should we assume that the field had autism
75 right the first time: while a prototype is the original, it is also by definition preliminary.

76

77 **Conflicts of interest**

78 The authors declare no conflicts of interest.

79

80 **References**

81 1 Mottron L, Bzdok D. Autism spectrum heterogeneity: fact or artifact?. *Mol Psychiatry*. 2020 Apr
82 30:1-8.

83 2 Kanner L. Autistic disturbances of affective contact. *Nervous child*. 1943 Apr;2(3):217-50.

84 3 Shefcyk A. Count us in: addressing gender disparities in autism research. *Autism*. 2015 February
85 19(2):131-132.

86 4 Russell G, Mandy W, Elliott D, White R, Pittwood T, Ford T. Selection bias on intellectual ability
87 in autism research: a cross-sectional review and meta-analysis. *Mol Autism*. 2019 Dec 1;10(1):9.

88 5 Beggiano A, Peyre H, Maruani A, Scheid I, Rastam M, Amsellem F, et al. Gender differences in
89 autism spectrum disorders: Divergence among specific core symptoms. *Autism Res*. 2017
90 Apr;10(4):680-9.

91 6 Hull L, Petrides KV, Mandy W. The female autism phenotype and camouflaging: A narrative
92 review. *Rev J Autism Dev Disord*. 2020 Jan 1:1-2.

93 7 American Psychiatric Association, American Psychiatric Association. DSM 5. **American**
94 **Psychiatric Association**. 2013 May 27;70.

95 8 Lever AG, Geurts HM. Psychiatric co-occurring symptoms and disorders in young, middle-aged,
96 and older adults with autism spectrum disorder. *J. Autism Dev. Disord*. 2016 Jun 1;46(6):1916-30.

97 9 Li J, Hu S, Zhang K, Shi L, Zhang Y, Zhao T, et al. A comparative study of the genetic components
98 of three subcategories of autism spectrum disorder. *Mol Psychiatry*. 2019 Nov;24(11):1720-31.

99 10 Antshel KM, Russo N. Autism spectrum disorders and ADHD: Overlapping phenomenology,
100 diagnostic issues, and treatment considerations. *Current psychiatry reports*. 2019 May;21(5):1-1.

101 11 Happé F, Ronald A, Plomin R. Time to give up on a single explanation for autism. *Nat Neurosci*.
102 2006 Oct;9(10):1218-20.

- 103 12 Brand A, Bradley MT. The precision of effect size estimation from published psychological
104 research: Surveying confidence intervals. *Psychological Reports*. 2016 Feb;**118**(1):154-70.
- 105 13 Molloy CA, Murray DS, Akers R, Mitchell T, Manning-Courtney P. Use of the Autism Diagnostic
106 Observation Schedule (ADOS) in a clinical setting. *Autism*. 2011 Mar;**15**(2):143-62.
- 107 14 Underwood JF, Kendall KM, Berrett J, Lewis C, Anney R, Van den Bree MB, et al. Autism
108 spectrum disorder diagnosis in adults: phenotype and genotype findings from a clinically derived
109 cohort. *Br J Psychiatry*. 2019 Nov;**215**(5):647-53.
- 110 15 Loomes R, Hull L, Mandy WP. What is the male-to-female ratio in autism spectrum disorder? A
111 systematic review and meta-analysis. *Journal of the American Academy of Child & Adolescent*
112 *Psychiatry*. 2017 Jun 1;**56**(6):466-74.